Determining the Vasohibin-1 Levels of the Serum and Broncoalveolar Lavage Fluid in the Patients with Lung Cancer”

Yıl 2022, Cilt: 14 Sayı: 2, 298 - 303, 29.06.2022

Alev Lazoglu Mevlüt Sait Keleş Esra Laloğlu Elif Yılmazel Ucar Sinan Yılmaz

https://doi.org/10.18521/ktd.1066032

Öz

Objective: Lung cancer constitutes 17% of all cancer cases and accounts for 23% of the deaths caused by cancer all over the world. Vasohibin-1 (VASH-1) is an angiogenesis-inhibiting factor synthesized by endothelial cells (ECs). This study aimed to examine the VASH-1 levels of the bronchoalveolar lavage (BAL) and serum in the patients with lung cancer.
Material and Method: A total of 82 patients participated in this study. 39 and 43 of them had a benign lung disease and lung cancer, respectively. The VASH-1 levels of serum and BAL were measured using the Enzyme-Linked Immunosorbent Assay (ELISA).
Results: The BAL VASH-1 levels of the patients in the lung cancer group were found to be statistically significantly lower than those of the patients in the benign lung disease group (p=0.032). No statistically significant difference was found between the individuals with lung cancer and benign lung disease in terms of the serum VASH-1 concentration (p=0.206). A statistically significantly moderate positive correlation was found between the serum and BAL VASH-1 levels in the benign and malignant cases (benign r=0.442, p=0.005; malignant r=0.364, p=0.016). When the lung cancer patients were categorized into pathological stages and histological types, no significant difference was found between the stages and histological types in terms of the serum and BAL fluid VASH-1 concentrations.
Conclusions: BAL VASH-1 concentrations decreased in the lung cancer patients compared to the individuals having a benign lung disease. Considering the results reached in this study, it was thought that the BAL VASH-1 concentrations might be beneficial in distinguishing between the benign and malignant lung diseases.

Anahtar Kelimeler

Angiogenesis, broncoalveolar lavage fluid, lung cancer, metastasis, vasohibin-1.

Destekleyen Kurum

Scientific Research Project of Ataturk University

Proje Numarası

PRJ2014/13

Akciğer Kanserli Hastalarda Serum ve Bronkoalveolar Lavaj Sıvısında Vasohibin-1 Düzeylerinin Belirlenmesi

Öz

Amaç:Akciğer kanseri tüm dünyada kanser olgularının %17’sinden, kanser ölümlerinin ise %23’ünden sorumludur. Vasohibin 1 (VASH-1) endotel hücreleri tarafından sentezlenen bir anjiyogenez inhibe edici faktördür. Bu çalışmada akciğer kanserli hastalarda, bronkoalveolar lavaj (BAL) ve serum VASH-1 düzeylerinin incelenmesi amaçlandı.
Gereç ve Yöntem: Bu çalışmaya toplam 82 hasta katıldı. Bunlardan 39'u benign akciğer hastalığı ve 43'ü malign akciğer kanserine sahipti. Serum ve BAL VASH-1 düzeyleri, enzim bağlı immünosorbent analizi (ELISA) kullanılarak ölçüldü.
Bulgular: Akciğer kanseri grubunda, BAL VASH1 düzeyleri, benign akciğer hastalığı olan gruptan anlamlı derecede düşüktü (p=0,032). Ancak serum VASH-1 düzeyleri açısından her iki grup arasında anlamlı bir fark yoktu (p=0,206). Malign ve benign vakalarda serum VASH-1 ile BAL VASH-1 düzeyleri arasında istatistiksel olarak anlamlı, orta dereceli, pozitif bir korelasyon vardı (benign r= r=0.442, p=0.005; malign r=0.364, p=0.016). Akciğer kanserli hastalar patolojik ‘stage’ lerine ve histolojik tiplerine göre ayrıldığında, evreler ve histolojik tipler arasında serum ve BAL sıvısı VASH1 konsantrasyonları bakımından anlamlı bir farklılık yoktu.
Sonuç: BAL VASH-1 konsantrasyonları, akciğer kanseri hastalarında benign akciğer hastalığı olan bireylere kıyasla azaldı. Elde edilen sonuçlar ışığında, BAL VASH-1 konsantrasyonlarının benign ve malign akciğer hastalıklarını ayırt etmede faydalı olabileceği düşünülmüştür.

Anahtar Kelimeler

Akciğer kanseri, Anjiogenez, Bronkoalveolar lavaj sıvısı, Metastaz, Vazohibin-1

Proje Numarası

PRJ2014/13

Kaynakça

• REFERENCES 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.
• 2. Goksel T, Akkoclu A, Turkish Thoracic Society L, Pleural Malignancies Study G. Pattern of lung cancer in Turkey, 1994-1998. Respiration; international review of thoracic diseases. 2002;69(3):207-10.
• 3. Schabath MB, Nguyen A, Wilson P, Sommerer KR, Thompson ZJ et al. Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung cancer. 2014.
• 4. Türk Toraks D. Akciğer kanseri tanı ve tedavi rehberi. Toraks Dergisi. 2006;7 (ek 2):1-37.
• 5. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest. 2003;123(1 Suppl):115S-28S.
• 6. Miyashita H, Watanabe T, Hayashi H, Suzuki Y, Nakamura T et al. Angiogenesis inhibitor vasohibin-1 enhances stress resistance of endothelial cells via induction of SOD2 and SIRT1. PloS one. 2012;7(10):e46459.
• 7. Sato Y, Sonoda H. The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells. Arteriosclerosis, thrombosis, and vascular biology. 2007;27(1):37-41.
• 8. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. The Journal of clinical investigation. 2004;114(7):898-907.
• 9. Sato Y. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. International journal of clinical oncology. 2003;8(4):200-6.
• 10. Kimura H, Miyashita H, Suzuki Y, Kobayashi M, Watanabe K et al. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood. 2009;113(19):4810-18.
• 11. Hosaka T, Kimura H, Heishi T, Suzuki Y, Miyashita H et al. Vasohibin-1 Expression in Endothelium of Tumor Blood Vessels Regulates Angiogenesis. Am J Pathol. 2009;175(1):430-9.
• 12. Zhao G, Yang Y, Tang Y, Han R and Sun Y. Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma. Med Oncol. 2012;29:3325-3334.
• 13. Kanomata N, Sato Y, Miyaji Y, Nagai A and Moriya T. Vasohibin-1 is a new predictor of disease-free survival in operated patients with renal cell carcinoma. J Clin Pathol. 2013;66:613-619.
• 14. Tamaki K, Moriya T, Sato Y, Ishida T, Maruo Y, Yoshinaga K, et al. Vasohibin-1 in human breast carcinoma: A potential negative feedback regulator of angiogenesis. Cancer science. 2009;100(1):88-94.
• 15. Tamaki K, Sasano H, Maruo Y, Takahashi Y, Miyashita M, Moriya T, et al. Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast. Cancer science. 2010;101(4):1051-8.
• 16. Murakami K, Kasajima A, Kawagishi N, Sekiguchi S, Fujishima F, Watanabe M, et al. The prognostic significance of vasohibin 1-associated angiogenesis in patients with hepatocellular carcinoma. Human pathology. 2014;45(3):589-97.
• 17. Zhang T, Yu TT, Zhang DM, Hou XM, Liu XJ, Zhao D, et al. Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer. Medical oncology. 2014;31(5):963.
• 18. Kosaka T, Miyazaki Y, Miyajima A, Mikami S, Hayashi Y, Tanaka N, et al. The prognostic significance of vasohibin-1 expression in patients with prostate cancer. British journal of cancer. 2013;108(10):2123-9.
• 19. Miyazaki Y, Kosaka T, Mikami S, Kikuchi E, Tanaka N, Maeda T, et al. The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma. Clinical Cancer Research. 2012;18(5):4145-53.
• 20. Yan Y, Shen Z, Ye Y, Jiang K, Zhang H, Shen C, et al. A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1. Medical oncology. 2014;31(2):816.
• 21. Almatroodi SA, McDonald CF, Collins AL, Darby IA, Pouniotis DS. Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. Cancer genomics & proteomics. 2015;12(1):39-48.
• 22.Alpay M. New Approach to Cancer: Anti-Angiogenic Treatment in Vitro Lung Cancer. Konuralp Tıp Dergisi 2019;11(1): 128-133.
• 23. Ito S, Miyashita H, Suzuki Y, Kobayashi M, Satomi S, Sato Y. Enhanced cancer metastasis in mice deficient in vasohibin-1 gene. PloS one. 2013;8(9):73931.
• 24. Watanabe T , Hosaka T , Ohmori-Matsuda K , Suzuki Y, et al. High preoperative plasma vasohibin‐1 concentration predicts better prognosis in patients with non–small cell lung carcinoma. Health Sci Rep. 2018;1(6):40.
• 25. Yoshinaga K, Ito K, Moriya T, Nagase S, Takano T, Niikura H, et al. Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas. Cancer science. 2011;102(2):446-51.
• 26. Kobayashi H , Kosaka T , Mikami S, et al. Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer. Oncotarget. 2018; 9:10203-10210.